Swedish Cancer Society Awards MedH Researchers Over 65 Million

In the Swedish Cancer Society's latest call, researchers at the Department of Medicine, Huddinge (MedH) have been awarded a total of SEK 65 650 000 for the years 2027-2029. The funding covers 20 research projects and one planning group.

A total of SEK 65 200 000 has been awarded in project grants and SEK 450 000 to the planning group Swedish Lymphoma Group (SLG). The recipients, projects and grant amounts are presented below.

Evren Alici , HERM

Granted: SEK 1 600 000 for 2027-2028.

Project title: Reprogramming the immune synapse to enable persistent universal NK cell therapies

Ann-Sofie Backman , GUT

Granted: SEK 800 000 for 2027.

Project title: Mesalamine for colorectal cancer prevention program in Lynch syndrome-a multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with Mesalamine(5-ASA) or placebo in LS carriers

Annika Bergquist , GUT

Granted: SEK 4 500 000 for 2027-2029.

Project title: Primary Sclerosing Cholangitis - A Premalignant Disease

Martin Bergö , ICCA

Granted: SEK 6 000 000 for 2027-2029.

Project title: Defining how nuclear CCL28, metastasis-promoting immune cells, and BACH1 drive tumor progression and metastasis

Niklas Björkström , CIM

Granted: SEK 3 000 000 for 2027-2028.

Project title: Decoding human determinants of tumor immune exclusion using monozygotic twins

Yenan Bryceson , HERM

Granted: SEK 3 500 000 for 2027-2028.

Project title: Understanding and harnessing lymphocyte cytotoxicity against solid tumors

Antonino Cassotta , HERM

Granted: SEK 3 000 000 for 2027-2029.

Project title: Dissecting the myeloma-reactive TCR repertoire to develop predictive models of clinical response to T cell engager therapy

Benedict Chambers , CIM

Granted: SEK 1 600 000 for 2027-2028.

Project title: Continued studies into the adhesion molecule JAML in anti-tumor immune responses

Rongrong Fan , GUT

Granted: SEK 1 000 000 for 2027.

Project title: X-linked epigenetic enzyme as a sex-specific regulator of tumor immunity in liver cancer

Sten Eirik Jacobsen , HERM

Granted: SEK 4 500 000 for 2027-2029.

Project title: Identification, characterization and therapeutic targeting of the stem cells of myeloid malignancies

Sören Lehmann , HERM

Granted: SEK 7 500 000 for 2027-2029.

Project title: Harnessing the epigenome and immune system to improve treatment of acute myeloid leukemia (AML) with focus on bcl-2 inhibition and TP53-mutated patients

Andreas Lennartsson , HERM

Granted: SEK 4 500 000 for 2027-2029.

Project title: Targeting epigenetic plasticity in pediatric acute leukemia

Vanessa Lundin , HERM

Granted: SEK 2 400 000 for 2027-2029.

Project title: Developmental Stem Cell Heterogeneity as a Determinant of Blood Cancer Risk

Jakob Michaëlsson , CIM

Granted: SEK 3 000 000 for 2027-2029.

Project title: Dissecting the functional regulation of lung tumor-infiltrating human NK Cells

Hong Qian , HERM

Granted: SEK 2 500 000 for 2027-2028.

Project title: Targeting leukemia niche to identify new therapeutic option

Stefano Romeo , CeRM

Granted: SEK 800 000 for 2027.

Project title: ELUCIDATING THE GENETIC ARCHITECTURE OF HEPATOCELLULAR CARCINOMA

Johan Sandberg , CIM

Granted: SEK 3 000 000 for 2027-2029.

Project title: The potential of innate-like MAIT cells in cancer: Immunobiology, tissue-specific specialization and immunotherapy

Staffan Strömblad , ICCA

Granted: SEK 6 000 000 for 2027-2029.

Project title: Cell-matrix interactions in cancer

Björn Wahlin , HERM

Granted: SEK 3 000 000 for 2027-2029.

Project title: Improved therapy and precision medicine for lymphoma

Martin Wohlwend , ICCA

Granted: SEK 3 000 000 for 2027-2029.

Project title: Identification and targeting of oncogenic RNA domains

Kristina Sonnevi , HERM - planning group

Granted: SEK 450 000 for 2027-2029.

Planning group: Swedish Lymphoma Group (SLG)

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.